CAR T-Cell Therapy

Engineering a patient's own immune cells to attack cancer — FDA-approved products, manufacturing, toxicity management, and disease-specific outcomes

Key Points

• CAR T-cell therapy genetically engineers a patient's own T cells to express a chimeric antigen receptor (CAR) that directly recognizes and kills tumor cells without requiring MHC presentation.
• FDA-approved products target CD19 (B-cell lymphomas, ALL), BCMA (multiple myeloma), and CD22 (B-ALL) — with rapidly expanding approvals in earlier lines of therapy.
• Cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) are the signature toxicities, graded by ASTCT criteria and managed with tocilizumab and dexamethasone.
• Lymphodepleting chemotherapy (fludarabine + cyclophosphamide) precedes CAR T infusion to create immunological "space" for CAR T expansion — it is essential, not optional.
• CAR T-cell therapy must be administered at FACT-certified or FDA-authorized treatment centers with specialized nursing staff, pharmacy, and ICU backup.
• Next-generation CAR T technologies — armored CARs, allogeneic "off-the-shelf" CARs, and dual-targeting CARs — are in active development to address antigen escape, exhaustion, and manufacturing delays.

The CAR T-Cell Platform: Engineering and Manufacturing

Chimeric antigen receptor T-cell (CAR T) therapy is a form of adoptive cellular immunotherapy in which a patient's own T lymphocytes are genetically modified to express an artificial receptor — the chimeric antigen receptor (CAR) — that enables them to recognize and destroy tumor cells with high specificity, independently of MHC antigen presentation. This MHC-independence is a key advantage over natural T cell recognition, which requires tumor cells to present antigens via intact HLA molecules — a mechanism many cancers evade by downregulating HLA expression. **CAR structure:** A CAR protein…

FDA-Approved CAR T-Cell Products

As of 2025, six autologous CAR T-cell products are FDA-approved for hematologic malignancies: **Anti-CD19 products (B-cell malignancies):** *Axicabtagene ciloleucel (Axi-cel; Yescarta — Kite/Gilead):* CD28 co-stimulatory domain; gammaretroviral vector. Approved for: (1) Relapsed/refractory large B-cell lymphoma (DLBCL, HGBL, PMBCL, FL Grade 3B) after ≥2 prior lines (ZUMA-1 trial: ORR 83%, CR 58%, 5-year OS 42%); (2) R/R DLBCL as second-line therapy in early relapse or primary refractory disease (ZUMA-7 trial: superior EFS vs. standard of care auto-HSCT); (3) R/R follicular lymphoma after ≥3…

Lymphodepleting Conditioning

Before CAR T-cell infusion, patients receive a conditioning regimen of lymphodepleting chemotherapy — most commonly **fludarabine 25–30 mg/m²/day × 3 days + cyclophosphamide 250–500 mg/m²/day × 3 days** (Flu/Cy), starting approximately 5–7 days before the CAR T infusion, with infusion on Day 0. Lymphodepleting chemotherapy is not merely preparatory cytoreduction — it is mechanistically essential to CAR T efficacy: 1. **Elimination of regulatory T cells (Tregs):** Tregs suppress T cell activity; their depletion creates a permissive immune environment for CAR T expansion. 2. **Elimination of…

Cytokine Release Syndrome (CRS)

Cytokine release syndrome (CRS) is the most common and expected acute toxicity of CAR T-cell therapy, occurring in 50–90% of patients to some degree. It results from the massive release of cytokines — primarily IL-6, IFN-γ, IL-1β, IL-10, and TNF-α — as CAR T cells proliferate in vivo and engage target cells. CRS can range from mild flu-like symptoms to life-threatening multi-organ dysfunction. **ASTCT 2019 grading criteria (replacing the older Lee/Porter/Penn criteria):** - **Grade 1:** Fever (temperature ≥38°C) without hypotension or hypoxia - **Grade 2:** Fever with hypotension responsive…

ICANS — Immune Effector Cell-Associated Neurotoxicity Syndrome

ICANS (formerly called CRES — CAR T-cell-related encephalopathy syndrome, or CART-neurotoxicity) is the second major toxicity of CAR T therapy, occurring in 20–60% of recipients, typically following the peak of CRS. It is caused by the breakdown of the blood-brain barrier by cytokines (particularly IL-1β, IL-6, and TNF-α) and the direct infiltration of CAR T cells into the CNS. **ASTCT 2019 ICANS grading:** ICE (Immune Effector Cell Encephalopathy) score assesses: orientation to year, month, city, hospital (4 points), naming ability (10 points), command-following (1 point), writing (1…

Other Toxicities and Long-Term Effects

**B-cell aplasia and hypogammaglobulinemia:** A predictable on-target off-tumor effect of anti-CD19 CAR T therapy — all normal CD19+ B cells are eliminated along with the malignant ones. This results in B-cell aplasia (detectable by flow cytometry) and progressive decline in immunoglobulin levels (IgG, IgA, IgM) over months. B-cell aplasia is actually a useful surrogate marker of CAR T persistence — as long as B cells are absent, CAR T cells are active. Patients require IVIG infusions (every 3–4 weeks, targeting IgG trough ≥400 mg/dL) to prevent bacterial and some viral infections. In ALL,…

Treatment Centers, Logistics, and Outpatient Administration

**Certification requirements:** CAR T-cell therapy is only available at treatment centers authorized by the respective manufacturers and certified by FACT (Foundation for Accreditation of Cellular Therapy) or ASCO. Certification requires: dedicated CAR T-cell coordinators, 24/7 CRS/ICANS monitoring capability, pharmacy with appropriate storage and handling, on-site apheresis capability, ICU with staff trained in CRS/ICANS management, and neurology support. Major academic medical centers and designated cancer centers are the principal sites; access in rural or community settings remains a…

Mechanisms of Resistance and Next-Generation CAR T

Despite remarkable response rates, a substantial proportion of patients relapse after CAR T therapy — approximately 40–60% within 2 years, depending on disease and product. Understanding resistance mechanisms is critical for developing next-generation strategies. **Antigen escape:** The most well-characterized resistance mechanism — tumor cells that have lost or downregulated the target antigen (CD19, BCMA) survive CAR T attack. CD19-negative relapse after anti-CD19 CAR T is well documented (Sotillo et al., Nature Medicine 2015). Strategies to overcome antigen escape: dual-targeting CARs…